DiscoveRx Corporation Signs Agreement with Cosmo Bio
News Feb 07, 2008
DiscoveRx Corporation announces the selection of Cosmo Bio Co., Ltd. as a key distributor for the Japanese territory.
“Cosmo Bio's leadership in providing third party drug discovery services to the Japanese pharmaceutical and biotech industries and in the distribution of products for life science research is well recognized throughout Japan. We believe that the addition of DiscoveRx Corporation’s Selectivity Screen™ GPCR profiling services will significantly benefit Cosmo Bio’s customers,” said Theresa Schaub, Director, Drug Discovery Screening Services at DiscoveRx.
Dr. Haruhisa Sakurai, Director of Cosmo Bio’s Drug Discovery Services team, remarked, “Many drugs relate to their effects via a family of proteins called G-protein-coupled receptors (GPCR). Many industries have focused the development of drugs as one of important targets. To accelerate discovery of more selective screening for disease, we are very excited by the opportunity to offer GPCR Profiling Service by DiscoveRx to Japanese customers.”
Additionally, DiscoveRx Corporation continues to add targets to its discovery service offering. The recent introduction of Nuclear Hormone Receptors, Kinases and Orphan GPCRs complement DiscoveRx Corporation’s PathHunter™ Cell Based Assays, HitHunter™ Biochemical Assays and screening reagents. Global adoption of the PathHunter™ EFC technology has contributed to discovery of compounds worldwide.
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
New Cell-weighing Technique Helps Predict How Drugs Affect Cancer CellsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE